$BBIO
BridgeBio Pharma, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021003080 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $12.89M $2.344M $8.127M
YoY Change 10638.33% -71.16% -69.61%
Cost Of Revenue $1.551M $1.454M $0.00
YoY Change -100.0%
Gross Profit $11.34M $890.0K $8.127M
YoY Change -89.05% -66.47%
Gross Profit Margin 87.96% 37.97% 100.0%
Selling, General & Admin $54.75M $46.08M $36.02M
YoY Change 46.23% 27.95% 53.26%
% of Gross Profit 483.01% 5177.98% 443.16%
Research & Development $122.2M $104.3M $92.05M
YoY Change 35.52% 13.31% 66.52%
% of Gross Profit 1078.08% 11719.66% 1132.64%
Depreciation & Amortization $1.526M $265.0K
YoY Change
% of Gross Profit 13.46% 29.78%
Operating Expenses $176.9M $150.4M $128.1M
YoY Change 38.66% 17.43% 57.58%
Operating Profit -$165.6M -$149.5M -$119.9M
YoY Change 24.65% 119.94%
Interest Expense -$14.95M $11.07M $10.93M
YoY Change 42.26% 1.26% 417.23%
% of Operating Profit
Other Income/Expense, Net $28.28M -$11.52M -$10.23M
YoY Change 849.13% 12.6% 66.8%
Pretax Income -$152.3M -$161.0M -$130.2M
YoY Change 12.78% 23.7% 114.59%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$147.2M -$161.0M -$130.2M
YoY Change 22.67% 23.7% 114.57%
Net Earnings / Revenue -1142.15% -6869.28% -1601.66%
Basic Earnings Per Share -$1.06
Diluted Earnings Per Share -$1.013M -$1.063M -$980.5K
COMMON SHARES
Basic Shares Outstanding 147.2M 146.7M
Diluted Shares Outstanding 146.7M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $836.7M $599.6M $710.7M
YoY Change 37.81% -15.63% 32.57%
Cash & Equivalents $393.8M $180.3M $367.0M
Short-Term Investments $442.9M $419.3M $343.7M
Other Short-Term Assets $52.19M $39.64M $26.70M
YoY Change 46.2% 48.45% 99.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $888.9M $639.7M $745.4M
YoY Change 38.27% -14.18% 33.55%
LONG-TERM ASSETS
Property, Plant & Equipment $30.07M $27.74M $25.80M
YoY Change 47.93% 7.52% 764.61%
Goodwill
YoY Change
Intangibles $44.93M $46.20M
YoY Change
Long-Term Investments $17.71M
YoY Change
Other Assets $33.03M $33.05M $16.50M
YoY Change 38.01% 100.33% 535.1%
Total Long-Term Assets $123.9M $141.8M $42.30M
YoY Change 103.96% 235.26% -48.65%
TOTAL ASSETS
Total Short-Term Assets $888.9M $639.7M $745.4M
Total Long-Term Assets $123.9M $141.8M $42.30M
Total Assets $1.013B $781.5M $787.7M
YoY Change 43.95% -0.78% 22.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.88M $12.04M $9.800M
YoY Change 32.86% 22.81% -4.58%
Accrued Expenses $122.9M $83.51M $60.70M
YoY Change 54.38% 37.57% 1167.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $295.0K $283.0K
YoY Change -79.77%
Total Short-Term Liabilities $135.1M $95.82M $75.70M
YoY Change 41.21% 26.58% 89.92%
LONG-TERM LIABILITIES
Long-Term Debt $430.8M $103.1M $471.9M
YoY Change 366.08% -78.14% 529.06%
Other Long-Term Liabilities $22.07M $27.58M $21.70M
YoY Change 131.82% 27.09% 1463.4%
Total Long-Term Liabilities $452.8M $130.7M $493.6M
YoY Change 344.2% -73.52% 546.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $135.1M $95.82M $75.70M
Total Long-Term Liabilities $452.8M $130.7M $493.6M
Total Liabilities $1.878B $1.517B $623.9M
YoY Change 215.32% 143.21% 436.63%
SHAREHOLDERS EQUITY
Retained Earnings -$1.437B -$1.290B
YoY Change 61.68%
Common Stock $841.7M $821.4M
YoY Change -17.6%
Preferred Stock
YoY Change
Treasury Stock (at cost) $275.0M $275.0M $75.00M
YoY Change 266.67% 266.67%
Treasury Stock Shares $6.192M $6.192M $2.415M
Shareholders Equity -$870.4M -$743.4M $163.8M
YoY Change
Total Liabilities & Shareholders Equity $1.013B $781.5M $787.7M
YoY Change 43.95% -0.78% 22.98%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$147.2M -$161.0M -$130.2M
YoY Change 22.67% 23.7% 114.57%
Depreciation, Depletion And Amortization $1.526M $265.0K
YoY Change
Cash From Operating Activities -$133.9M -$121.6M -$131.7M
YoY Change 39.1% -7.68% 163.41%
INVESTING ACTIVITIES
Capital Expenditures -$2.536M -$6.462M -$550.0K
YoY Change 17.95% 1074.91% 44.74%
Acquisitions
YoY Change
Other Investing Activities $24.34M $65.43M -$44.50M
YoY Change -71.42% -247.03% -77.41%
Cash From Investing Activities $21.80M $58.97M -$45.05M
YoY Change -73.74% -230.89% -77.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 325.4M -135.5M 2.780M
YoY Change 7082.8% -4972.52% -99.24%
NET CHANGE
Cash From Operating Activities -133.9M -121.6M -131.7M
Cash From Investing Activities 21.80M 58.97M -45.05M
Cash From Financing Activities 325.4M -135.5M 2.780M
Net Change In Cash 213.3M -198.0M -173.9M
YoY Change -2548.75% 13.85% -244.74%
FREE CASH FLOW
Cash From Operating Activities -$133.9M -$121.6M -$131.7M
Capital Expenditures -$2.536M -$6.462M -$550.0K
Free Cash Flow -$131.4M -$115.1M -$131.1M
YoY Change 39.58% -12.23% 164.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q3 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
bbio:OtherAccruedLiabilitiesCurrent1Member
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember
CY2021Q3 us-gaap Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherNoncurrentAssetsMember
CY2020Q3 us-gaap Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherNoncurrentAssetsMember
CY2021Q3 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherNoncurrentLiabilitiesMember
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001743881
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38959
dei Entity Registrant Name
EntityRegistrantName
BridgeBio Pharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1850815
dei Entity Address Address Line1
EntityAddressAddressLine1
421 Kipling Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94301
dei City Area Code
CityAreaCode
(650)
dei Local Phone Number
LocalPhoneNumber
391-9740
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
BBIO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1563000
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
147166573
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180347000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
356082000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
419264000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
251011000
CY2021Q3 bbio Receivable Current From Licensing And Collaboration Agreements
ReceivableCurrentFromLicensingAndCollaborationAgreements
7710000
CY2021Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
462000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
31927000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
35731000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
639710000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
642824000
CY2021Q3 bbio Investments In Equity Securities
InvestmentsInEquitySecurities
17707000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27741000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20325000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17108000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16508000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
46204000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33054000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23931000
CY2021Q3 us-gaap Assets
Assets
781524000
CY2020Q4 us-gaap Assets
Assets
703588000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
12035000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8945000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21560000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
29682000
CY2021Q3 bbio Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
37645000
CY2020Q4 bbio Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
27290000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4976000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5579000
CY2020Q4 bbio Leo Call Option Liability Current
LEOCallOptionLiabilityCurrent
5550000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4999000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3795000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1458000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14608000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13349000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
95823000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
95648000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
103138000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
92421000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18683000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14677000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
27578000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9520000
CY2021Q3 us-gaap Liabilities
Liabilities
1517398000
CY2020Q4 us-gaap Liabilities
Liabilities
595702000
CY2021Q3 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
2967000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
1630000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
153279652
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
147087891
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125264070
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
122849389
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
153000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
125000
CY2021Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
6191761
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
2414681
CY2021Q3 us-gaap Treasury Stock Value
TreasuryStockValue
275000000
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
75000000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
821220000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1021344000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
192000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1289789000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-888755000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-743397000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
57906000
CY2021Q3 us-gaap Minority Interest
MinorityInterest
4556000
CY2020Q4 us-gaap Minority Interest
MinorityInterest
48350000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-738841000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
106256000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
781524000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
703588000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2344000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8127000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56830000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8127000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1454000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
104305000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
92050000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
328824000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
246873000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46084000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36016000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
137461000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
108247000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
151843000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
128066000
us-gaap Costs And Expenses
CostsAndExpenses
467848000
us-gaap Costs And Expenses
CostsAndExpenses
355120000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-149499000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-119939000
us-gaap Operating Income Loss
OperatingIncomeLoss
-411018000
us-gaap Operating Income Loss
OperatingIncomeLoss
-346993000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
234000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
692000
us-gaap Investment Income Interest
InvestmentIncomeInterest
951000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3567000
CY2021Q3 us-gaap Interest Expense
InterestExpense
11067000
CY2020Q3 us-gaap Interest Expense
InterestExpense
10929000
us-gaap Interest Expense
InterestExpense
31644000
us-gaap Interest Expense
InterestExpense
25693000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-684000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7539000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1344000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11517000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10228000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23154000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23470000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-161016000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-130167000
us-gaap Profit Loss
ProfitLoss
-434172000
us-gaap Profit Loss
ProfitLoss
-370463000
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5081000
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-14308000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-18810000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-41720000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-155935000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-115859000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-415362000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-328743000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.06
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.98
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
118168063
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
144044360
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.88
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.79
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
146662756
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
117663038
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-161016000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-130167000
us-gaap Profit Loss
ProfitLoss
-434172000
us-gaap Profit Loss
ProfitLoss
-370463000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-397000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-173000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
207000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-161033000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-130564000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-434345000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-370256000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-5081000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-14308000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-18810000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-41720000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-155952000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-116256000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-415535000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-328536000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
106256000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19841000
CY2021Q1 bbio Adjustments To Additional Paid In Capital Purchase Of Capped Calls
AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls
-61295000
CY2021Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
50000000
CY2021Q1 bbio Repurchase Of Noncontrolling Interests Transaction Costs
RepurchaseOfNoncontrollingInterestsTransactionCosts
70734000
CY2021Q1 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
-91997000
CY2021Q1 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
5080000
CY2021Q1 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-517000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-249000
CY2021Q1 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-170206000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-389365000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32509000
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
5308000
CY2021Q2 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
5000
CY2021Q2 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
3618000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
93000
CY2021Q2 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-100512000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-457490000
CY2021Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
144692000
CY2021Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
734000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16896000
CY2021Q3 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
640000
CY2021Q3 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
362000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
CY2021Q3 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-159680000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-738841000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
473733000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8063000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
167726000
CY2020Q1 bbio Adjustments To Additional Paid In Capital Purchase Of Capped Calls
AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls
-49280000
CY2020Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
75000000
CY2020Q1 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
26565000
CY2020Q1 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-574000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
472000
CY2020Q1 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-103216000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
449018000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7295000
CY2020Q2 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
3537000
CY2020Q2 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-431000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
132000
CY2020Q2 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-134636000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
325606000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11748000
CY2020Q3 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
7267000
CY2020Q3 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-799000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-397000
CY2020Q3 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-129036000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
215813000
us-gaap Profit Loss
ProfitLoss
-434172000
us-gaap Profit Loss
ProfitLoss
-370463000
us-gaap Share Based Compensation
ShareBasedCompensation
79731000
us-gaap Share Based Compensation
ShareBasedCompensation
46313000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4317000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1021000
bbio Noncash Lease Expense
NoncashLeaseExpense
4078000
bbio Noncash Lease Expense
NoncashLeaseExpense
2169000
us-gaap Accretion Expense
AccretionExpense
4043000
us-gaap Accretion Expense
AccretionExpense
12315000
bbio Call Option Expense Income
CallOptionExpenseIncome
-5550000
bbio Call Option Expense Income
CallOptionExpenseIncome
1120000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-8513000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4134000
bbio Increase Decrease Receivable From Licensing And Collaboration Agreements
IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements
7710000
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
462000
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
5155000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3743000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5391000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
8930000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
194000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1360000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
547000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4443000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2395000
bbio Increase Decrease In Accrued Research And Development Liabilities
IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities
4686000
bbio Increase Decrease In Accrued Research And Development Liabilities
IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities
4004000
bbio Increase Decrease In Accrued Professional Service
IncreaseDecreaseInAccruedProfessionalService
346000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
183079000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
367391000
bbio Increase Decrease In Accrued Professional Service
IncreaseDecreaseInAccruedProfessionalService
1151000
bbio Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4474000
bbio Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2309000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1629000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4890000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-364039000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-303453000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
575478000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
269802000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
305200000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
139016000
bbio Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
98925000
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
23960000
us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
4743000
bbio Proceeds From Consolidation Of Entities
ProceedsFromConsolidationOfEntities
13654000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
35000000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
147000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10710000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5372000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-222626000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-136011000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
747500000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
550000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
16064000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
13039000
bbio Purchase Of Capped Calls
PurchaseOfCappedCalls
61295000
bbio Purchase Of Capped Calls
PurchaseOfCappedCalls
49280000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
198458000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
75000000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
24094000
bbio Proceeds From Issuance Of Noncontrolling Interest
ProceedsFromIssuanceOfNoncontrollingInterest
3500000
bbio Proceeds From Issuance Of Noncontrolling Interest
ProceedsFromIssuanceOfNoncontrollingInterest
2000000
bbio Repurchase Of Noncontrolling Interest Including Direct Transaction Costs
RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts
85090000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
25000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
18108000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3821000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1205000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4035000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
243000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14294000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2921000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
411065000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
442658000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-175600000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3194000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
358679000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
364197000
us-gaap Interest Paid Net
InterestPaidNet
28239000
us-gaap Interest Paid Net
InterestPaidNet
13281000
bbio Net Non Cash Portion Of Repurchase Of Noncontrolling Interests
NetNonCashPortionOfRepurchaseOfNoncontrollingInterests
38167000
bbio Direct Transaction Costs In Repurchase Of Noncontrolling Interest Recorded In Additional Paid In Capital Previously Classified In Prepaid Expenses And Other Current Assets
DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets
8749000
bbio Noncash Or Part Noncash Contributions Made By Noncontrolling Interests
NoncashOrPartNoncashContributionsMadeByNoncontrollingInterests
21600000
bbio Deferred Merger Transaction Costs Included In Accounts Payable And Accrued Professional Services
DeferredMergerTransactionCostsIncludedInAccountsPayableAndAccruedProfessionalServices
1527000
bbio Recognized Intangible Asset Recorded In Other Accrued Liabilities And Other Long Term Liabilities
RecognizedIntangibleAssetRecordedInOtherAccruedLiabilitiesAndOtherLongTermLiabilities
12500000
us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
2449000
bbio Repurchase Of Common Stock Recorded In Accounts Payable
RepurchaseOfCommonStockRecordedInAccountsPayable
1542000
bbio Recognition Of Property And Equipment Previously Classified In Other Assets
RecognitionOfPropertyAndEquipmentPreviouslyClassifiedInOtherAssets
10000000
bbio Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest
NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest
-221000
bbio Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest
NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest
9572000
us-gaap Nature Of Operations
NatureOfOperations
<div style="display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.3402777777777778in;">1.</span><div id="organizationanddescription" style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Organization and De</span><span id="n1_organization_description_business"/><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">scription of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Business </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BridgeBio Pharma, Inc. (“BridgeBio”) was established to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company’s two approved therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since inception, BridgeBio has either created wholly-owned subsidiaries or made investments in certain controlled entities, including partially-owned subsidiaries for which BridgeBio has a majority voting interest, and variable interest entities (“VIEs”) for which BridgeBio is the primary beneficiary (collectively, “we”, “our”, “us”). BridgeBio is headquartered in Palo Alto, California.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reclassifications</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain reclassifications have been made to the condensed consolidated statement of cash flows for the nine months ended September 30, 2020 to conform to the current year's presentation. These reclassifications had no net effect on cash flows from operating, financing and investing activities as previously reported.</span></p>
bbio Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
P90D
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180347000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
366967000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
176000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2556000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
424000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
183079000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
367391000
CY2021Q3 bbio Straight Line Operating Lease Costs
StraightLineOperatingLeaseCosts
1457000
CY2020Q3 bbio Straight Line Operating Lease Costs
StraightLineOperatingLeaseCosts
995000
bbio Straight Line Operating Lease Costs
StraightLineOperatingLeaseCosts
4078000
bbio Straight Line Operating Lease Costs
StraightLineOperatingLeaseCosts
2684000
CY2021Q3 bbio Finance Lease Straight Line Finance Lease Costs
FinanceLeaseStraightLineFinanceLeaseCosts
88000
bbio Finance Lease Straight Line Finance Lease Costs
FinanceLeaseStraightLineFinanceLeaseCosts
205000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to, accruals for research and development activities and contingent clinical, development, regulatory and sales-based milestone payments in our in-licensing agreements and asset acquisitions, the valuation of our stock-based awards, accruals for performance-based milestone compensation arrangements, accounting for stock-based award modifications, the present value of lease payments of our leases on the respective lease commencement dates, the expected recoverability and estimated useful lives of our long-lived assets, the fair value of the LianBio Warrants (see Note 7) and the fair value of the LEO call option liability (see Note 7). We base our estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9520000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8425000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1021344000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
853266000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-888755000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-874427000
CY2021Q3 bbio Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount
FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2020Q4 bbio Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount
FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2021Q3 bbio Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount
FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2020Q4 bbio Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount
FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
488889000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
47000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
28000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
488908000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
517256000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
196000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
517448000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2021Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
bbio Short Term Marketable Securities Contractual Maturities
ShortTermMarketableSecuritiesContractualMaturities
P7M
CY2021Q3 bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
-500000
bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
-200000
CY2020Q3 bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
1100000
bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
9600000
CY2021Q3 bbio Potential Milestone Fixed Monetary Amount Settlement In Cash
PotentialMilestoneFixedMonetaryAmountSettlementInCash
10799000
CY2021Q3 bbio Potential Milestone Accrued Amount Settlement In Cash
PotentialMilestoneAccruedAmountSettlementInCash
985000
CY2021Q3 bbio Potential Milestone Fixed Monetary Amount Settlement In Stock
PotentialMilestoneFixedMonetaryAmountSettlementInStock
121128000
CY2021Q3 bbio Potential Milestone Accrued Amount Settlement In Stock
PotentialMilestoneAccruedAmountSettlementInStock
11973000
CY2021Q3 bbio Potential Milestone Fixed Monetary Amount Settlement In Cash Or Stock At Sole Discretion
PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion
108928000
CY2021Q3 bbio Potential Milestone Accrued Amount Settlement In Cash Or Stock At Sole Discretion
PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion
3949000
CY2021Q3 bbio Potential Milestone Fixed Monetary Settlement Amount
PotentialMilestoneFixedMonetarySettlementAmount
240855000
CY2021Q3 bbio Potential Milestone Accrued Settlement Amount
PotentialMilestoneAccruedSettlementAmount
16907000
CY2021Q3 bbio Accrued Termination Charges
AccruedTerminationCharges
0
CY2020Q4 bbio Accrued Termination Charges
AccruedTerminationCharges
0
CY2021Q3 bbio Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
6317000
CY2021Q3 bbio Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
38000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
27720000
CY2021Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1860000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
257000
us-gaap Variable Lease Cost
VariableLeaseCost
2831000
us-gaap Variable Lease Cost
VariableLeaseCost
558000
CY2021Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
7643000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
21666000
CY2021Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
848000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2388000
CY2021Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
23000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
70000
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
8514000
us-gaap Interest Expense Debt
InterestExpenseDebt
24124000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
7715000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10186000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
528000
us-gaap Interest Expense Debt
InterestExpenseDebt
18429000
CY2020Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.088
bbio Asset Acquisitions And In Licensing Agreement Disclosure Textblock
AssetAcquisitionsAndInLicensingAgreementDisclosureTextblock
<div style="display:flex;margin-top:18.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.3402777777777778in;">12.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Asset Acquisitions, In-licensing and Other Agreements</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Novartis License Agreement</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2018, QED entered into a License Agreement with Novartis International Pharmaceutical, Inc. (“Novartis”), pursuant to which QED acquired certain intellectual property rights, including patents and know-how, related to infigratinib for the treatment of patients with FGFR-driven diseases. QED accounted for the transaction as an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified asset, in-process research and development (“IPR&amp;D”), thus satisfying the requirements of the screen test in ASU 2017-01, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business Combinations (Topic 805), Clarifying the Definition of a Business</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The assets acquired and liabilities assumed in the transaction were measured based on their fair values. The fair value of the IPR&amp;D acquired was charged to research and development expense as it had no alternative future use at the time of the acquisition.</span></p><p style="text-indent:5.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If certain substantial milestones are met, QED could be required to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in regulatory milestone payments, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in sales-based milestone payments, and pay royalties of up to low double-digit percentages on net sales. Following the FDA approval of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TRUSELTIQ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in May 2021, we paid a one-time regulatory milestone payment to Novartis of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. We capitalized such payment as a finite-lived intangible asset and amortize the amount over its estimated useful life on a straight-line basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Asset Purchase Agreement with Alexion</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2018, our subsidiary Origin Biosciences, Inc. (“Origin”) entered into an Asset Purchase Agreement with Alexion Pharma Holding Unlimited Company (“Alexion”) to acquire intellectual property rights, including patent rights, know-how, and contracts, related to the ALXN1101 molecule. Origin accounted for the transaction as an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified asset, IPR&amp;D, thus satisfying the requirements of the screen test in ASU 2017-01. The assets acquired and liabilities assumed in the transaction were measured based on their fair values. The fair value of the IPR&amp;D acquired was charged to research and development expense as it had no alternative future use at the time of the acquisition.</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Asset Purchase Agreement, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Origin could be required to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million if a certain condition is met. Such a condition was met in 2021, resulting in a one-time final payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three months ended September 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which we capitalized as a finite-lived intangible asset and amortize it over its estimated useful life on a straight-line basis. In addition, under the Asset Purchase Agreement, Origin could be required to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in sales-based milestone payments and royalties of up to low double-digit percentages on net sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diagnostics Agreement with Foundation Medicine</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2018, QED and Foundation Medicine, Inc. (“FMI”) entered into a companion diagnostics</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> agreement relating to QED’s drug discovery and development initiatives. Pursuant to the agreement, QED could be required to pay $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in regulatory approval milestones over a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> subsequent to the FDA approval of a companion diagnostic for TRUSELTIQ in patients with cholangiocarcinoma. The FDA approved the companion diagnostic for TRUSELTIQ in May 2021, which resulted in the capitalization of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a finite-lived intangible asset to be amortized over its estimated useful life on a straight-line basis. As of September 30, 2021, the amount due to FMI is presented in our condensed consolidated balance sheets in “Other accrued liabilities” and “Other long-term liabilities” for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:5.067%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the intangible assets recognized in connection with the above agreements:</span></p><p style="text-indent:5.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:74.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.961%;"/> <td style="width:24.752%;"/> <td style="width:2.333%;"/> <td style="width:2.747%;"/> <td style="width:20.524%;"/> <td style="width:1.681%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average <br/>Estimated Useful Lives</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">September 30, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross amount</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,500</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated amortization</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,296</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net book value included in “Other assets”</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,204</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization expense recorded as part of cost of products sold for the three and nine months ended September 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. Future amortization expense is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the remainder of 2021, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for each of the years from 2022 to 2025 and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million thereafter.</span>
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P12Y9M18D
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
47500000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1296000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
46204000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1200000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
3700000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
3700000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
3700000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
3700000
CY2021Q3 bbio Finite Lived Intangible Assets Amortization Expense Rolling After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour
30000000.0
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4038000
CY2021Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
248000
CY2021Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
27000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
83000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1111000
CY2021Q3 us-gaap Lease Cost
LeaseCost
2683000
CY2020Q3 us-gaap Lease Cost
LeaseCost
1252000
us-gaap Lease Cost
LeaseCost
7197000
us-gaap Lease Cost
LeaseCost
3242000
us-gaap Operating Lease Payments
OperatingLeasePayments
4474000
us-gaap Operating Lease Payments
OperatingLeasePayments
2749000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
101000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
0
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
71000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6380000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
11814000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M12D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2021Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0558
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0591
CY2021Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0662
CY2020Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1214000
CY2021Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
66000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6455000
CY2021Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
420000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5289000
CY2021Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
432000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4478000
CY2021Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
445000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18683000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
23682000
CY2021Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
283000
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1329000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3967000
CY2021Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
459000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4999000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
23682000
CY2021Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1612000
CY2021Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1612000
CY2021Q1 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2600000
CY2019Q4 bbio One Time Fees Receivable Noncurrent
OneTimeFeesReceivableNoncurrent
10000000.0
CY2021Q3 bbio Payable Related To Manufacturing Suite
PayableRelatedToManufacturingSuite
2000000.0
CY2020Q4 bbio Payable Related To Manufacturing Suite
PayableRelatedToManufacturingSuite
4000000.0
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16130000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
83061000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17699000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
46313000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39222976
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26180686

Files In Submission

Name View Source Status
R23.htm Edgar Link pending
0000950170-21-003080-index-headers.html Edgar Link pending
0000950170-21-003080-index.html Edgar Link pending
0000950170-21-003080.txt Edgar Link pending
0000950170-21-003080-xbrl.zip Edgar Link pending
bbio-20210930.htm Edgar Link pending
bbio-20210930.xsd Edgar Link pending
bbio-20210930_cal.xml Edgar Link unprocessable
bbio-20210930_def.xml Edgar Link unprocessable
bbio-20210930_htm.xml Edgar Link completed
bbio-20210930_lab.xml Edgar Link unprocessable
bbio-20210930_pre.xml Edgar Link unprocessable
bbio-ex10_1.htm Edgar Link pending
bbio-ex31_1.htm Edgar Link pending
bbio-ex31_2.htm Edgar Link pending
bbio-ex32_1.htm Edgar Link pending
bbio-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending